Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response.
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response.
复制标题
吡格列酮用于治疗糖尿病前期或 2 型糖尿病患者的 NASH——作者的反应。
DOI：
10.1136/gutjnl-2017-314263
复制
发表时间：
2018
期刊：
影响因子：
24.5
通讯作者：
Sanyal,ArunJ
中科院分区：
文献类型：
--
作者：
Rotman,Yaron;Sanyal,ArunJ
我们要感谢Cusi教授1指出了重要的随机对照试验2的遗漏，在该试验中，他和他的同事基本上确认并巩固了吡格列酮治疗非酒精性脂肪性肝炎（NASH）有效性的证据。我们同意Cusi教授的观点，吡格列酮可以被认为是NASH患者有效和有效的治疗选择，尽管有效性必须与对其长期安全性的担忧进行权衡。我们只能希望我们的审查和他对此的评论将提高人们的认识，并提高目前对其使用的有限接受度。4
We would like to thank Professor Cusi 1 for pointing out the omission of the important randomised controlled trial, 2 in which he and his colleagues have essentially confirmed and consolidated the proof for the effectiveness of pioglitazone in treating non-alcoholic steatohepatitis (NASH). We agree with Professor Cusi that pioglitazone could be considered a valid and effective treatment option for patients with NASH, although effectiveness has to be weighed against the concerns about its long-term safety. We can only hope that our review 3 and his commentary on it will enhance awareness and raise the current limited acceptance of its use. 4